<DOC>
	<DOC>NCT02468193</DOC>
	<brief_summary>The study aim is to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.</brief_summary>
	<brief_title>Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Cardiac Complexes, Premature</mesh_term>
	<mesh_term>Cushing Syndrome</mesh_term>
	<mesh_term>Adrenocortical Adenoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>ACTH Syndrome, Ectopic</mesh_term>
	<criteria>Patients confirmed Cushing's syndrome [i.e. ectopic corticotropin syndrome, adrenal adenoma, adrenal carcinoma, ACTHIndependent Macronodular Adrenal Hyperplasia (AIMAH), or Primary Pigmented Nodular Adrenal Dysplasia (PPNAD)] For patients on medical treatment for hypercortisolism due to Cushing's syndrome, the washout periods must be completed prior to baseline efficacy assessments Patients with Cushing's disease History of hypersensitivity to osilodrostat or to drugs of similar chemical classes History of malignancy of any organ system, treated or untreated, within the past 5 years Patients receiving treatment for within 4 weeks or â‰¤5 x halflife of the agent (whichever is longer) before first dose of osilodrostat Patients with risk factors for QTc prolongation or Torsade de Pointes Other protocol defined Inclusion/Exclusion may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cushing's syndrome</keyword>
	<keyword>osilodrostat</keyword>
	<keyword>LCI699</keyword>
	<keyword>ectopic corticotropin syndrome</keyword>
	<keyword>adrenal adenoma</keyword>
	<keyword>adrenal carcinoma</keyword>
	<keyword>ACTH-Independent Macronodular Adrenal Hyperplasia</keyword>
	<keyword>AIMAH</keyword>
	<keyword>Primary Pigmented Nodular Adrenal Dysplasia</keyword>
	<keyword>PPNAD</keyword>
</DOC>